1-3 of 3
Papiya Sinha
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Quantitative Immunofluorescence Reveals the Signature of Active B-cell Receptor Signaling in Diffuse Large B-cell Lymphoma

Available to Purchase
Agata M. Bogusz, Richard H.G. Baxter, Treeve Currie, Papiya Sinha, Aliyah R. Sohani, Jeffery L. Kutok, Scott J. Rodig
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (22): 6122–6135.
https://doi.org/10.1158/1078-0432.CCR-12-0397
Published: 14 November 2012
View articletitled, Quantitative Immunofluorescence Reveals the Signature of Active B-cell Receptor Signaling in Diffuse Large B-cell Lymphoma
Open the PDF for Quantitative Immunofluorescence Reveals the Signature of Active B-cell Receptor Signaling in Diffuse Large B-cell Lymphoma in another window
Includes: Supplementary data
Journal Articles

Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non–Small Cell Lung Cancer

Available to Purchase
Takeshi Shimamura, Samanthi A. Perera, Kevin P. Foley, Jim Sang, Scott J. Rodig, Takayo Inoue, Liang Chen, Danan Li, Julian Carretero, Yu-Chen Li, Papiya Sinha, Christopher D. Carey, Christa L. Borgman, John-Paul Jimenez, Matthew Meyerson, Weiwen Ying, James Barsoum, Kwok-Kin Wong, Geoffrey I. Shapiro
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (18): 4973–4985.
https://doi.org/10.1158/1078-0432.CCR-11-2967
Published: 16 September 2012
View articletitled, Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non–Small Cell Lung Cancer
Open the PDF for Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy

Available to Purchase
Michael R. Green, Scott Rodig, Przemyslaw Juszczynski, Jing Ouyang, Papiya Sinha, Evan O'Donnell, Donna Neuberg, Margaret A. Shipp
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (6): 1611–1618.
https://doi.org/10.1158/1078-0432.CCR-11-1942
Published: 14 March 2012
View articletitled, Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy
Open the PDF for Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy in another window
Includes: Supplementary data